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Summary  The  Gulf  Cooperation  Council  Center  for  Infection  Control  (GCC-IC)  has
placed  the  emergence  of  antimicrobial  resistance  (AMR)  on  the  top  of  its  agenda
for  the  past  four  years.  The  board  members  have  developed  the  initial  draft  for  the
GCC  strategic  plan  for  combating  AMR  in  2014.  The  strategic  plan  stems  from  theAMR;
GCC;
WHO  mandate  to  combat  AMR  at  all  levels.  The  need  for  engaging  a  large  number
of  stakeholders  has  prompted  the  GCC-IC  to  engage  a  wider  core  of  professionals
in  ﬁnalizing  the  plan.  A  multi-disciplinary  group  of  more  than  40  experts  were  thenSaudi  Arabia;
United  Arab  Emirates;
Qatar;
identiﬁed.  And  a  workshop  was  conducted  in  Riyadh  January  2015  and  included,
for  the  ﬁrst  time,  representation  of  relevant  ministries  and  agencies  as  well  as
international  experts  in  the  ﬁeld.  Participants  worked  over  a  period  of  two  and  a
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half  days  in  different  groups.  International  experts  shared  the  global  experiences  and
challenges  in  addressing  human,  food,  animal,  and  environmental  aspects  of  control-
ling  AMR.  Participants  were  then  divided  into  4  groups  each  to  address  the  human,
animal,  microbiological  and  diagnostic,  or  the  environmental  aspect  of  AMR.  At  the
end  of  the  workshop,  the  strategic  plan  was  revised  and  endorsed  by  all  participants.
The  GCC-IC  board  members  then  approved  it  as  the  strategic  plan  for  AMR.  The  doc-
ument  produced  here  is  the  ﬁrst  GCC  strategic  plan  addressing  AMR,  which  shall  be
adopted  by  GCC  countries  to  develop  country-based  plans  and  related  key  perfor-
 It  is  now  the  role  of  each  country  to  identify  the  body  that
mplementing  the  plan  at  the  country  level.
Bahrain;
Oman;
Kuwait
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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otic resistant  bacteria  [22,23]. And  similar  to  other
countries  worldwide,  the  GCC  countries  face  chal-
lenges with  adherence  of  healthcare  providers  tomance  indicators  (KPIs).
will  be  accountable  for  i
©  2016  King  Saud  Bin  Ab
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Introduction
The  ongoing  emergence  and  spread  of  antimicro-
bial resistance  (AMR)  in  bacteria  is leading  medicine
to a post-antibiotic  era  [1,2].  Urinary-tract  infec-
tions (UTI),  for  example,  are  increasingly  caused
by bacteria  that  are  resistant  to  last-line  antibi-
otics  [3,4].  Gram-negative  bacilli  colistin  resistance
[5]  and  Pan-drug  resistance  are  being  reported
more frequently  [6,7]. In  essence,  antimicrobial
resistance is  not  a  new  phenomenon  [8].  Identiﬁ-
cation of  penicillin-resistant  bacterial  strains  has
been documented  as  early  as  1940  [9].  While  the
reliance  on  antimicrobial  agents  has  led  to  the
advancement  of  medicine  that  we  see  today,  such
as implantable  devices  through  complex  surgical
procedures, organ  and  stem  cell  transplant,  and
cures for  many  advanced  cancers  that  have  led  to
the survival  of  signiﬁcantly  immunocompromised
patients.  These  interventions  would  not  have  been
possible without  the  existence  of  antimicrobial
agents [10].  On  the  other  hand,  the  misuse  of  these
agents  through  the  lack  of  hospital  and  community-
based stewardship  programs,  poor  compliance  with
infection control  policies,  limited  incentives  for
developing  new  agents,  lack  of  global  surveillance,
and limited  availability  of  affordable  rapid  diagnos-
tics for  AMR,  have  all  played  a  signiﬁcant  role  in
enhancing  the  emergence  and  widespread  distribu-
tion of  AMR  [11]. This  is  a  true  threat  to  modern
medicine as  we  know  it  today.
To mitigate  this  threat,  the  WHO  launched  the
Global Action  Plan  on  Antimicrobial  Resistance  with
the ‘‘One  Health’’  approach  [12].  Despite  this  not
being the  ﬁrst  attempt  for  a  global  action  plan,
the ‘‘One  Health’’  approach  is  in  desperate  need  of
recognition  and  global  acknowledgment.  The  plan
consists of  ﬁve  pillars:  to  improve  awareness  of
AMR, to  increase  knowledge  through  surveillance,
to reduce  the  incidence  of  infection,  to  optimize
i
h
d
she  use  of  antimicrobial  agents,  and  to  develop
he economic  case  for  sustainable  investment  in
ll countries  with  regards  to  new  and  affordable
edicines, diagnostic  tools,  vaccines,  and  other
nterventions  [12]. As  a response  to  this  action  plan
ifferent  countries,  including  the  United  Kingdom
13], Australia  [14], Canada  [15], and  the  United
tates [16], initiated  their  own  national  AMR  action
lans. The  most  notable  similarity  between  them
s the  willingness  of  the  countries  to  tackle  AMR
n human  and  animal  health  as  well  as  in  food,
griculture, and  the  environment  sectors.  Here,  we
escribe the  GCC  initiative  to  join  the  global  com-
unity in  addressing  AMR.
he increasing threat of AMR in the GCC
tates
ountries  of  the  Gulf  Cooperation  Council  (GCC)
re a political  and  economic  union.  Constituent
ountries include:  The  Kingdom  of  Saudi  Ara-
ia, Sultanate  Oman,  United  Arab  Emirates  (UAE),
uwait, Qatar,  and  the  Kingdom  of  Bahrain.  Sev-
ral factors  have  been  linked  to  the  emergence
nd spread  of  AMR  in  this  region  [17,18]. Heavy
nternational travel  due  to  the  large  population
f expatriate  workers,  booming  tourism  in  sev-
ral of  the  countries,  and  the  hosting  of  over  4
illion  pilgrims  throughout  the  year  to  the  holy
ities  of  Mecca  and  Madinah  in  the  Kingdom  of
audi Arabia  [19—22]; where  travel  is  a known
isk factor  for  acquiring  and  transmitting  antibi-nfection  control  practices.  The  lack  of  primary
ealthcare systems  and  legislation  on  the  pru-
ent and  responsible  use  of  antimicrobials  is a
hared concern.  Most  hospitals  have  no  established
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fhe  GCC  strategic  plan  for  combating  AMR  
tewardship  programs  and  community  pharmacies
requently dispense  antimicrobial  agents  with  no
rescription  [17].  Furthermore,  the  use  of  antibi-
tics is prevalent  and  without  supervision  in  the
reatment  of  animals,  and  in  some  of  the  countries
here is  growing  evidence  that  antibiotics  are  used
s growth  promoters  [24,25]. As  a  result,  a sig-
iﬁcant  AMR  burden  has  been  described  in  the
CC region  [26,27]; including:  Extended  Spectrum
eta-Lactamase  (ESBL)  producing  bacteria  [20,28],
arbapenemase-producing  bacteria  [29],  Pan-drug-
esistant  Gram-negative  bacilli  (GNB)  [6],  as  well  as
ultidrug-resistant  tuberculosis  [27].  Between  60
nd 90%  of  Klebsiella  pneumoniae  isolates  are  ESBL
roducers  [18],  which  is  associated  with  up  to  40%
ortality  [30].  Additionally,  60—90%  of  Acinetobac-
er causing  ventilator-associated  pneumonia  were
hown to  be  resistant  to  most  tested  antimicrobials,
ncluding carbapenems,  with  signiﬁcant  negative
linical  impact  [29,31]. Multidrug  resistant  orga-
isms were  implicated  in  20%  of  mortality  caused
y bloodstream  infections  in  pediatric  hematol-
gy/oncology patients  [32].
More recent  region-wide  surveillance  studies
eported more  alarming  results.  The  majority  of
arbapenem  Resistant  Enterobacteriaceae  (CRE)
rom the  GCC  have  been  found  to  possess
laOXA-48-type,  and  blaNDM-1 carbapenemase  [33].
ulti-drug Carbapenem-resistant  K.  pneumoniae
nfection from  the  GCC  countries  were  found  to
roduce  OXA-48  and  were  associated  with  hospi-
al outbreaks  and  hospitalization  mortality  [30,34].
dditionally, several  reports  from  GCC  countries
howed that  Carbapenem  resistant  Acinetobacter
aumannii (CRAB)  is  producing  OXA-23-type  Car-
apenemase  [35—39]. Large  clusters  of  CRAB  have
een found  to  be  identical  not  only  to  other  isolates
ithin  hospitals  but  also  to  isolates  found  in  hospi-
als located  across  borders  [36]. This  might  explain
hy the  majority  of  CRAB  is  found  to  be  associated
ith healthcare  exposures  [36], and  the  increasing
ncidence of  CRAB-related  outbreaks  in  the  region
20,40].  Another  recent  study  found  that  the  diges-
ive tracts  of  6%  of  ICU  patients  were  colonized  with
XA-23-producing  CRAB  [35].
The  identiﬁcation  of  novel  and  rare  resistance
echanisms  in  patients  from  the  GCC  countries
emonstrates  that  the  region  might  harbor  other
ntibiotic  resistance  mechanisms  in  addition  to
hat is  commonly  known  or  what  has  been  pub-
ished. PME-1  Pseudomonas  aeruginosa, isolated
rom  Qatar,  belongs  to  the  ‘high-risk’  clone  ST654
41],  a  clone  that  is known  to  cause  infections
n many  different  parts  of  the  world  [42—44].
dditionally,  the  identiﬁcation  of  the  Pan-drug-
esistant K.  pneumoniae,  which  belongs  to  the
e
l
f
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nternationally  disseminated  ST147  and  has  a
istory of  causing  outbreaks  [45—52],  is  a  very  sig-
iﬁcant  ﬁnding.  The  recently  published  literature  is
n eye  opener  to  the  potential  catastrophic  future
f AMR  in  the  region,  which  requires  attention.
The AMR  issue  in  GCC  countries  is  not  only
estricted to  GNB.  In  a recent  study  from  Riyadh,
taphylococcus aureus  was  found  in  40%  of  the
asal cavities  of  200  tested  healthcare  workers
nd that  45%  were  methicillin-resistant  S.  aureus
MRSA),  making  the  total  prevalence  of MRSA  car-
iage in  the  study  18%  [53]. Another  study  analyzed
he antibiotic  susceptibility  proﬁles  for  a range  of
treptococcus  pneumoniae, and  found  that  the  rate
f penicillin  resistance  was  72%  [54].  On  the  other
and,  a national  survey  on  Anti-tuberculosis  drug
esistance  found  that  only  1.6%  of  all  TB  strains
emonstrated MDR  phenotype  [55].
he leading role of the GCC-center for
nfection control to combat AMR in the
egion
he  cooperative  nature  among  the  GCC  countries
as expanded  to  cover  health-related  aspects,  as
emonstrated  by  the  establishment  of  the  Exec-
tive Board  of  Health  Ministers’  Council  for  GCC
tates  in  1991  and  the  GCC  center  for  Infection
ontrol (GCC-IC)  in  2005.  The  GCC-IC  was  estab-
ished  to  assist  the  member  countries  in  creating
nd executing  a shared  vision  toward  internation-
lly recognized  infection  prevention  and  control
rograms in  the  region  [56—59]. During  the  early
stablishment of  the  GCC-IC,  expertise  and  knowl-
dge to  develop  the  aims  and  goals  for  the  center
ere shared.  It  was  clear  that  building  human
apacity in  the  ﬁeld  of  infection  control  and  devel-
ping  a standardized  method  of practice  were  two
ajor priorities.  The  center  developed  a  uniﬁed
nfection control  manual  as  a  reference  for  the
ountries on  best  practices  in  infection  control
57]. The  manual  based  its  policies  on  the  estab-
ished  international  guidelines  of  the  WHO,  CDC
nd major  healthcare  societies  such  as  the  Society
or Healthcare  Epidemiology  of  America  (SHEA)  and
he Association  for  Professionals  in  Infection  Con-
rol and  Epidemiology  (APIC).  The  GCC  infection
ontrol manual  is  now  in  its  second  edition  [57].
 second  publication  was  produced  on  surveillance
or healthcare  associated  infection  (HAI),  also  in  an
ffort to  unify  surveillance  methodology  with  the
ong term  goal  of  developing  a  regional  bench  mark
or HAIs  [58,59]. The  GCC-IC  has  led  and  partici-
ated in  many  educational  activities  in  the  region
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geared  toward  infection  control  workshops,  surveil-
lance  training  programs,  hand  hygiene  monitoring
education workshops,  and  many  other  programs,
including a  biannual  GCC-IC  symposium,  hosted  by
a GCC  member  country.
The process of developing the GCC AMR
strategic plan
AMR  rose  to  the  top  of  the  GCC-IC  board  meeting
agenda in  2013.  During  the  ﬁrst  months  of  discussing
AMR,  the  countries  shared  their  experience  and
conducted  a  situational  analysis  that  discussed  in
detail the  gaps  identiﬁed  and  the  efforts  needed  to
combat AMR.  The  involvement  of  multiple  stake-
holders and  the  fact  that  they  report  to  ministries
or agencies  other  than  the  Ministry  of  Health  was  a
clear initial  challenge  that  needed  to  be  addressed.
The members  conducted  a  detailed  literature
review on  AMR  and  developed  the  initial  draft  for
the GCC  AMR  strategic  plan  in  2014.  The  next  step
was to  engage,  through  a  workshop,  all  necessary
stakeholders for  input  and  to  ﬁnalize  the  strategic
plan for  the  countries  to  adopt.  In  January  2015,
the GCC-IC  arranged  for  the  workshop  and  ﬁnalized
the AMR  strategic  plan  described  here.  Participants
of the  workshop  included  representatives  from  Min-
istry of  Health,  Ministry  of  Agriculture,  Infectious
Disease Societies,  Academic  and  Research  Centers,
and Food  and  Drug  Authority  and  were  from  all
GCC countries.  In  April  2015,  the  center  managed
to ﬁnalize  the  GCC  AMR  strategic  plan  represent-
ing the  collective  expert  views  of  the  stakeholders;
which complements  the  global  action  plan  issued  by
the WHO  in  2001  and  again  in  2015  [12].  It  is  very
important to  emphasize  that  this  GCC  strategic  plan
for combating  AMR  does  not  replace  the  need  for
developing  tailored  national  strategic  plans.
This endeavor  is  following  the  lead  of  the
European Union  (EU),  whose  AMR  initiative  is  a
remarkable  example  [60].  By  sharing  statistics,  uni-
fying surveillance  methods,  and  transparency  in
revealing  the  strength  and  limitations  of  their  data;
the EU  plays  a  leading  role  in  policy  development
and experience  sharing  for  the  sake  of  reducing  the
impact  of  AMR  in  their  countries,  as  well  as  others.
A second  example  of  addressing  AMR  in  a  challeng-
ing environment  was  by  India  in  announcing  the
Chennai  declaration  [61].  The  declaration  resulted
after  the  ﬁrst  meeting  of  most  medical  societies  in
India and  representatives  from  local  and  interna-
tional medical  and  health  authorities.  The  meeting
discussed  the  need  to  tackle  AMR  and  set  a plan  to
draw a  road  map  addressing  the  AMR  challenge  from
the Indian  perspective  [61]. The  following  sectionEditorial
s  summarizing  the  recommendations  addressed  in
he GCC  strategic  plan  for  combating  AMR.
he GCC strategic plan for combating
MR
ive  strategic  aims  are  identiﬁed  as  the  pillars  of
he GCC  AMR  strategic  plan:  ﬁrst,  countries  must
evelop an  understanding  of  the  magnitude  of  AMR
n the  GCC  countries  among  humans  and  animals,
s well  as  in  agriculture  and  the  environment.
econd,  countries  must  restrict  the  use  of  the  avail-
ble and  limited  effective  agents  to  preserve  their
fﬁciency.  Third,  countries  should  develop  early
dentiﬁcation  capacity  for  emerging  MDR  microor-
anisms.  Fourth,  countries  should  limit  the  spread
f resistant  pathogens  through  patients,  animals,
nd agriculture. Finally,  countries  must  encourage
ollaborative research  activities  regarding  AMR  in
umans, animals,  and  the  environment.
There are  clear  and  signiﬁcant  challenges  in
ddressing this  plan  in  different  countries.  The  ini-
ial challenge  is  soliciting  support  from  leadership.
eads of  state  need  to  be  able  to  empower  and
old responsible  ministries/agencies  accountable
or adopting  the  plan.  Another  challenge  is,  agree-
ng on  the  appropriate  key  performance  indicators
KPIs). Further,  is  to  provide  the  logistical  support
or the  execution  and  maintenance  of  any  initiative
n any  and  all  involved  sectors.
In summary,  the  GCC  AMR  strategic  plan
ddressed herein  aims  to  draw  a  road  map  for  the
mplementation  of  a tailored  national  action  plan  in
very GCC  country.  The  action  plan  is  particularly
mportant for  improving  adherence  to  stringent
nfection control  measures,  applying  regulations
ontrolling antibiotic  use  in  both  human  and  ani-
al sectors,  implementing  proactive  surveillance
f resistance,  and  enhance  awareness  and  educa-
ion about  AMR  among  healthcare  workers,  public,
eterinarians,  and  the  food  sectors.
lements of the strategic plan
I. Develop  an  understanding  of  the  magnitude  of
AMR in  the  GCC  countries  among  humans  and
animals as  well  as  in  agriculture  and  the  envi-
ronment
- Laboratory  (human):
Measurable  elements:
a.  Ensure  access  to  microbiology  laboratory
services that  match  the  level  of  those
provided  by  hospitals  (e.g.,  secondary,  ter-
tiary).
TIhe  GCC  strategic  plan  for  combating  AMR  
b.  Ensure  performance  and  quality  assurance
of appropriate  diagnostic  tests,  microbial
identiﬁcation,  antimicrobial  susceptibility
tests of  key  pathogens,  and  the  timely  and
relevant reporting  of  results.
c. Ensure  that  laboratory  data  are  recorded,
preferably  in  an  electronic  database,  and
are used  to  produce  clinically  and  epi-
demiologically  useful  surveillance  reports
of resistance  patterns  among  common
pathogens  and  infections  in  a  timely  man-
ner with  feedback  to  prescribers  and  to  the
infection control  program.
d. Adopt  an  international  system  of  antimicro-
bial breakpoints  interpretation  (in  microbi-
ology laboratories  in  the  GCC).
- Infection  prevention  and  control  (human)
Measurable  elements:
a.  Characterize  the  rates  of  MRSA,  van-
comycin  resistant  Enterococci  (VRE),
Clostridium  difﬁcile,  and  CRE  using  data
from GCC  hospitals.
b. Characterize  and  quantify  MDR  related
hospital-acquired  infections  (HAIs)  using
available data  on  healthcare  associated
infections  routinely  collected  from  GCC
hospitals.
- Laboratory  (animals)
Measurable  elements:
a.  Generate  baseline  and  periodic  point
prevalence  studies  on  antimicrobial  use  in
animals based  on  the  World  Organization
for Animal  Health  (OIE)  standards  and  using
data from  the  Ministry  of  Agriculture  (MoA)
[62].  In  addition  to  the  generation  of  data,
this will  ensure  compliance  with  the  WHO
list of  Critically  Important  Antimicrobials
(CIA)  for  Human  Health  as  described  by  the
WHO Advisory  Group  on  Integrated  Surveil-
lance of  Antimicrobial  Resistance  (AGISAR)
[63].
b. Generate  baseline  and  periodic  point
prevalence  data  on  the  presence  of  antimi-
crobial residue  in  food  of  animal  origin  with
necessary collaboration  between  the  Min-
istry of  Health  (MOH),  and  Drug  Authorities.
I. Preserve  the  available  and  limited  effective
agents for  human  use
- Legislation
Measurable  elements:
a.  Link  the  dispensing  of  all  antimicrobial
agents  to  a  prescription  and  unique  pre-
scriber/pharmacist  identiﬁers.b. Identify  a  restricted  list  of  antibiotics  that
will not  be  available  in  community  phar-
macies.379
c.  Monitor  the  trend  of  the  amount  of
antimicrobial  use  through  a deﬁned
daily does/days  of  therapy  (DDD/DOT)
[64].
d. Develop  standards  for  selecting  and  using
generic antimicrobial  agents  that  meet
international  standards  of  quality,  safety,
and efﬁcacy  when  granting  marketing
authorization.
e. Restrict  the  use  of  the  CIA  in animals
[62,63].
f. Require  obligatory  prescriptions  by
licensed veterinarians  for  all  antimicro-
bials used  for  disease  control  in  food
animals.
g. Terminate  or  rapidly  phase  out  the  use  of
antimicrobials for  growth  promotions.
h. Create  national  systems  to  monitor  antimi-
crobial usage  in  food  animals  according  to
the World  Organization  for  Animal  Health
(OIE) standards  [65].
i. Introduce  legal  requirements  for  man-
ufacturers to  collect  and  report  data
on antimicrobial  distribution  (including
import/export).
j. Create  economic  incentives  for  the  appro-
priate use  of  antimicrobials.
k.  Introduce  requirements  for  pharmaceuti-
cal companies  to  comply  with  national  or
international codes  of  practice  on  promo-
tional activities.
l. Ensure  that  national  or  international  codes
of practice  cover  direct-to-consumer
advertising,  including  advertising  on  the
Internet.
m. Develop  and  legislate  adult  and  pedi-
atric vaccine  programs  including,  but  not
limited to,  inﬂuenza,  pneumococcal,  and
conjugate meningococcal  vaccines.
- Prescriber
Measurable  elements:
a.  Educate  all  groups  of  antimicrobial  pre-
scribers and  dispensers  on:
• The  importance  of  appropriate  antimi-
crobial use  and  containment  of  antimi-
crobial resistance.
• Disease  prevention,  speciﬁcally,  immu-
nization programs  and  infection  control.
• Factors  that  may  strongly  inﬂuence
their  prescribing  habits,  such  as  eco-
nomic incentives,  promotional  activities
and inducements  by  the  pharmaceutical
industry.•  Educating  patients  on  antimicrobial  use
and the  importance  of  adherence  to  pre-
scribed treatments.
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b.  Encourage  the  development  and  use  of
Antimicrobial  guidelines  and  treatment
algorithms  to  foster  the  appropriate  use  of
antimicrobials.
c. Improve  antimicrobial  use  by  the  super-
vision and  support  of  clinical  practices,
especially  diagnostic  and  treatment  strate-
gies.
d. Audit  prescribing  and  dispensing  prac-
tices and  utilize  peer  group  or  external
standard  comparisons  to  provide  feedback
and endorsements  of  appropriate  antimi-
crobial prescribing.
e. Promote  targeted  undergraduate  and  post-
graduate educational  programs  on  the
accurate diagnosis  and  management  of
common infections  for  all  health  care
providers  and  veterinarians.
f.  Establish  an  Essential  Drugs  List  (EDL)  con-
sistent with  national  and  WHO  STGs  and
ensure the  accessibility  and  quality  of  these
drugs [66].
- Patient
Measurable  elements:
a.  Educate  patients  and  the  general  commu-
nity on  the  appropriate  use  of  antimicro-
bials.
b. Educate  patients  on  the  importance  of
measures to  prevent  infection,  such  as
immunization,  hygiene,  and  cough  eti-
quette.
c. Educate  patients  on  suitable  alternatives
to antimicrobials  for  the  relief  of  symp-
toms, and  discourage  patient  self-initiation
of treatment,  except  in  speciﬁc  circum-
stances.
d. Educate  patients  on  simple  measures  that
may reduce  transmission  of  infection  in  the
household and  community,  such  as  hand
washing, food  hygiene,  and  so  on.
e. Encourage  appropriate  and  informed  health
care seeking  behavior.
f.  Educate  students  in  primary,  elementary,
and high  schools  about  personal  hygiene  and
how  to  prevent  the  spread  of  infections.
I. Develop  the  ability  for  the  early  identiﬁcation  of
emerging  MDR  microorganisms
-  Improve  access  to  and  the  use  of  surveillance
data in  human,  animal,  food,  and  environment
sectors through  new  arrangements  that  facil-
itate greater  consistency  and  standardization
of the  data  collected  across  the  system  and
encourage improved  data  linkage
Measurable  elements:
a.  Adopt  a  uniﬁed  method  to  conduct  system-
atic surveillance  on  MDR  organisms  fromEditorial
the  clinical  laboratories  through  available
WHO tools  and  make  the  data  publicly
available  for  the  policy  makers  and  the
public
b. Adopt  a uniﬁed  method  to  identify  the  bur-
den of  MDR  organisms  on  HAIs  starting  by
major HAIs  such  as  central  line-associated
bloodstream  infection  (CLABSI),  ventilator-
associated  pneumonia  (VAP),  and  surgical
site infections  (SSIs);  and  make  the  data
publicly available  to  policy  makers  and  the
public [58].
c.  Designate  or  develop  reference  microbi-
ology laboratory  facilities  to  coordinate
effective  epidemiologically  sound  surveil-
lance of  antimicrobial  resistance  among
common pathogens  in  the  community,  hos-
pitals, and  other  health  care  facilities.
d. Adopt  World  Organization  for  Animal
Health (OIE)  standards  for  surveillance  in
the animal  sector  [65].
- Make  the  responsible  body  accountable  to  the
prompt  action  on  these  data
Measurable  elements:
a.  Identify  infection  prevention  and  control
(IPC) programs  in  the  hospital  as  sepa-
rate departments  reporting  to  the  highest
authority.
b. Make  IPC  accountable  for  leading  such
activities outlined  in  (a)  and  (b)  of  the  pre-
vious point.
. Limit the  spread  of  resistant  pathogens  through
patients, animals,  and  agriculture
- Humans
Measurable  elements:
a.  Monitor  and  improve  infection  prevention  and
control  practices  in  healthcare  facilities.
b. Establish  an  inter  hospital  transfer  system
that ensures  the  identiﬁcation  of  patients
with MDR  organisms  between  hospitals  in  one
country  and  the  transfer  of  patients  between
hospitals to  and  from  different  GCC  countries
to encourage  proper  isolation  precautions.
c. Improve  the  healthcare  systems  within  the
GCC countries  to  ensure  minimum  infection
control requirements  while  contracting  new
facilities or  renovating  old  ones.
- Animals:
Measurable  elements:
a.  Monitor  and  improve  infection  prevention
and control  practices  in  animal  health,  both
through the  enhanced  dissemination  and
implementation of  best  practices  and  the
better use  of  data,  diagnostics,  and  vaccines.
b. Enhance  the  availability  of  veterinarians
to prioritize  the  diagnosis  of  disease  in
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livestock,  poultry,  and  companion  animals
and to  encourage  the  early  use  of  appropri-
ate diagnostic  testing,  in  particular,  bacterial
culture and  sensitivity  testing.
c. Make  available  the  use  of  vaccines  in  hus-
bandry.
d. Encourage  livestock  farmers  to  adhere  to
government guidance  regarding  bio-security,
animal husbandry  and  for  farm  health  plan-
ning for  each  of  the  major  farming  sectors
and to  take  proactive  measures  to  reduce
the risk  of  disease  occurring  in  their  ani-
mals under  experienced  veterinarian  supervi-
sion.
e. Consider  the  use  of  ‘farm  assurance  schemes’
as a  mechanism  to  increase  adherence  to
best husbandry  including  the  isolation  of
sick animals,  testing  new  stock,  and  the
responsible use  of  antibiotic  by  veterinari-
ans only  while  ensuring  animal  health  and
welfare.
f. Encouraging  retailers  to  review  their  stan-
dards for  meat  and  animal  products  and
to set  clear  speciﬁcations  concerning  bio-
security, antimicrobial  stewardship  and  good
husbandry  throughout  the  supply  chain  for
overseas  as  well  as  national  meat  and  ani-
mal products,  working  with  suppliers  and
veterinarians  to  ensure  compliance,  all  in
accordance with  the  World  Trade  Organiza-
tion (WTO)  guidelines  that  are  set  by  World
Organization  for  Animal  Health  (OIE),  the
Food and  Agriculture  Organization  (FAO),  the
Codex,  and  the  Intergovernmental  Panel  on
Climate  Change  (IPPC)  [67—70].
g. Implement  standard  screening  protocols  for
animal  trading.
. Encourage  collaborative  research  activities
regarding AMR  in  humans,  animals  and  the
environment
Measurable elements:
a.  Identify  and  provide  ﬁnancial  support  for
research projects  in  the  AMR  ﬁeld  as  a
national priority.
b. Make  academic  centers  and  funding  agencies
within the  GCC  countries  aware  of  this  prior-
ity.
c. Include  all  relevant  sectors,  such  as  health-
care, food  and  drug  regulatory  agencies,
veterinarian  care,  and  agriculture  and  envi-
ronmental agencies.
d.  Conduct  research  that  measures  the  effec-
tiveness of  interventions  such  as  drug
restriction,  guidelines,  campaigns,  and  other
strategies.381
oving forward
igniﬁcant  progress  on  this  issue  has  been  accom-
lished  through  the  past  few  years.  Networking
as taken  place  to  identify  key  players.  They  have
cknowledged  the  importance  of  AMR  and  the
mmediate  need  for  a  national/regional  strategic
ction plan.  The  plan  is  now  at  the  stage  of  full
daptation at  the  highest  national  level  and  for
ountries  to  identify  an  accountable  body  to  over-
ee it’s  implementation.  This  will  take  time  to
stablish, allocate  resources,  and  identify  KPIs  as
ell as  to  train  the  involved  personal.  In  order  to
ustain this  momentum,  the  GCC-IC  will  conduct  an
nnual AMR  workshop  to  address  the  success  and
hare experiences  on  the  progress  and  challenges
f implementation.  Further,  countries  will  be  given
 platform  to  announce  and  raise  awareness  on  this
ssue through  the  Journal  of  Infection  and  Public
ealth  (JIPH).  In  the  upcoming  issues  of  this  journal
ountry  speciﬁc  achievements  will  be  published.
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